AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29641245 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Resonance by Cutaneous Stimulation (ERCS)
Number of subjects: 318
Study 29641245 — intervention group
Group type: COMPARATOR
Intervention: No ERCS (control group)
Number of subjects: 318
Study 27986129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning prior to PCI
Number of subjects: 251
Study 27986129 — intervention group
Group type: COMPARATOR
Intervention: Control group (only PCI)
Number of subjects: 251
Study 24942592 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMSCs transplantation
Number of subjects: 56
Study 24942592 — intervention group
Group type: COMPARATOR
Intervention: Entecavir treatment
Number of subjects: 56
Study 22237722 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation (SES) applied with different electrode positions
Number of subjects: 10
Study 22237722 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (age- and gender-matched)
Number of subjects: 10
Study 20357150 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 63
Study 20357150 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 63
Study 17373176 — intervention group
Group type: EXPERIMENTAL
Intervention: Desonide hydrogel 0.05%
Number of subjects: 425
Study 17373176 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel vehicle
Number of subjects: 425
Study 14510994 — intervention group
Group type: EXPERIMENTAL
Intervention: N-chlorotaurine (NCT)
Number of subjects: 40
Study 14510994 — intervention group
Group type: COMPARATOR
Intervention: Chloramine T (CAT)
Number of subjects: 40
Study 11127439 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor treatment started 3.2 ± 1.7 hours after MI
Number of subjects: 845
Study 11127439 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 845
Study 8747506 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood ethanol concentrations (0.00%, 0.01‐0.049%, 0.050‐0.099%, 0.10‐0.15%)
Number of subjects: 10
Study 8747506 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased punishment certainty or severity
Number of subjects: 10
Study 1575341 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-G needle
Number of subjects: 730
Study 1575341 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-G needle
Number of subjects: 730
Study 6476072 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern California Postrotary Nystagmus Test (SCPNT) under bright and dim conditions
Number of subjects: 18
Study 6476072 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern California Postrotary Nystagmus Test (SCPNT) under dark condition
Number of subjects: 18
Study 6476072 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronystagmography (ENG) measures under all three lighting conditions
Number of subjects: 18
Study 30842083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 30842083 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab
Number of subjects: 0
Study 27918718 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab plus Bevacizumab (Ona + Bev)
Number of subjects: 129
Study 27918718 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Bevacizumab (Pla + Bev)
Number of subjects: 129
Study 25872027 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 200
Study 23689708 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (ZnSO4) 125 mg daily for 14 days
Number of subjects: 16
Study 21838569 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting‐skills training plus intensive diet and activity education (P + DA)
Number of subjects: 111
Study 21838569 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting‐skills training alone (P)
Number of subjects: 111
Study 21838569 — intervention group
Group type: COMPARATOR
Intervention: Wait‐listed control (WLC)
Number of subjects: 111
Study 21838569 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 111
Study 19470793 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-enriched, low glycemic index, high fermentable fiber diet (1.5 cups of cooked dry beans)
Number of subjects: 23
Study 19470793 — intervention group
Group type: COMPARATOR
Intervention: Control diet (isocaloric average American diet)
Number of subjects: 23
Study 17924360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignoring centres
Number of subjects: 200
Study 17924360 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating centres as random effects
Number of subjects: 200
Study 17924360 — intervention group
Group type: COMPARATOR
Intervention: Including centres as fixed effects
Number of subjects: 200
Study 15285602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatically enriched contexts for 8-year-old children
Number of subjects: 2
Study 15285602 — intervention group
Group type: EXPERIMENTAL
Intervention: Logical responses to infelicitous 'some' statements among adults
Number of subjects: 2
Study 15285602 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory capacity among adults
Number of subjects: 2
Study 10893655 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin
Number of subjects: 16
Study 10893655 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid paracetamol
Number of subjects: 16
Study 10893655 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid
Number of subjects: 16
Study 8973072 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) treatment
Number of subjects: 47
Study 8973072 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 47
Study 8973072 — intervention group
Group type: COMPARATOR
Intervention: Tourette's syndrome patients
Number of subjects: 47
Study 8973072 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to SSRI
Number of subjects: 47
Study 1333637 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin 5000 IU and dihydroergotamine 0.5 mg 8 h‐1
Number of subjects: 18
Study 1333637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (Kabi‐Pharmacia, Sweden) 2500 IU 12 h‐1 on the day of surgery and 5000 IU 24 h‐1 throughout the observation period
Number of subjects: 18
Study 1333637 — intervention group
Group type: COMPARATOR
Intervention: dextran 500 ml 12 h‐1 on the day of surgery and 500 ml on days 1, 3, and 5 postoperatively
Number of subjects: 18
Study 6368776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent lipid infusion (8 hours/day)
Number of subjects: 28
Study 6368776 — intervention group
Group type: COMPARATOR
Intervention: Continuous lipid infusion (24 hours/day)
Number of subjects: 28
Study 6368776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 28
Study 30997492 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy diet (HDD: 5-6 dairy portions)
Number of subjects: 45
Study 30997492 — intervention group
Group type: COMPARATOR
Intervention: Low dairy diet (LDD: ≤1 dairy portion)
Number of subjects: 45
Study 30997492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (HDD and LDD)
Number of subjects: 45
Study 28742409 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3 plus 1000 mg evening primrose oil (EPO)
Number of subjects: 60
Study 28742409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27450743 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction intervention
Number of subjects: 235
Study 27450743 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 235
Study 24952576 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated Triglyceride (rTG) fish oil: EPA of 650 mg, DHA of 450 mg
Number of subjects: 35
Study 24952576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl Ester (EE) fish oil: EPA of 756 mg, DHA of 228 mg
Number of subjects: 35
Study 24952576 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride (TG) salmon oil: EPA of 180 mg, DHA of 220 mg
Number of subjects: 35
Study 24952576 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid (PL) krill oil: EPA of 150 mg, DHA of 90 mg
Number of subjects: 35
Study 24952576 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated Triglyceride (rTG) fish oil
Number of subjects: 35
Study 24952576 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil and (unconcentrated) triglyceride oil
Number of subjects: 35
Study 21701796 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 21701796 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 21701796 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0
Study 21701796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20686429 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin + Bevacizumab (PCB)
Number of subjects: 878
Study 20686429 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/Carboplatin (PC)
Number of subjects: 878
Study 20686429 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin + Bevacizumab (PCB) for adenocarcinoma
Number of subjects: 878
Study 20686429 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/Carboplatin (PC) for adenocarcinoma
Number of subjects: 878
Study 18984244 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative testing (experimental group)
Number of subjects: 153
Study 18984244 — intervention group
Group type: COMPARATOR
Intervention: Individual testing (control group)
Number of subjects: 153
Study 16158737 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment including complex physical factors (CAP‐ELM‐01)
Number of subjects: 42
Study 16158737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study 14703267 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment models for homeless individuals with severe mental illness; details on dosage and duration not available.
Number of subjects: 0
Study 14703267 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs assessment studies; details on intervention not available.
Number of subjects: 0
Study 14703267 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ESID approach; details on intervention not available.
Number of subjects: 0
Study 10788729 — intervention group
Group type: EXPERIMENTAL
Intervention: SSHIP-I participants
Number of subjects: 371
Study 10788729 — intervention group
Group type: EXPERIMENTAL
Intervention: SSHIP-II participants
Number of subjects: 371
Study 10788729 — intervention group
Group type: EXPERIMENTAL
Intervention: SSHIP-I women
Number of subjects: 371
Study 10788729 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in physical activity
Number of subjects: 371
Study 8884297 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Stapling Technique (SST)
Number of subjects: 103
Study 8884297 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Stapling Technique (DST)
Number of subjects: 103
Study 8884297 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 103
Study 1948658 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg intravenous methylprednisolone before ECMO
Number of subjects: 21
Study 1948658 — intervention group
Group type: COMPARATOR
Intervention: Control (no steroids)
Number of subjects: 21
Study 30053788 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic functional assessment within 48 hours of admission
Number of subjects: 336
Study 30053788 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate rehabilitation initiated within five days after discharge
Number of subjects: 336
Study 30053788 — intervention group
Group type: COMPARATOR
Intervention: Usual assessment
Number of subjects: 336
Study 30053788 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation
Number of subjects: 336
Study 30053788 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic functional assessment and immediate rehabilitation
Number of subjects: 336
Study 30918434 — intervention group
Group type: EXPERIMENTAL
Intervention: Khubchandani's procedure with stapled posterior rectal wall resection (group A)
Number of subjects: 93
Study 30918434 — intervention group
Group type: COMPARATOR
Intervention: STARR procedure (group B)
Number of subjects: 93
Study 28742515 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program with a trained physiotherapist
Number of subjects: 145
Study 28742515 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol as adjunct analgesia
Number of subjects: 145
Study 25846577 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on TZD
Number of subjects: 310
Study 25846577 — intervention group
Group type: COMPARATOR
Intervention: Add-on glimepiride
Number of subjects: 310
Study 25846577 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on exenatide twice daily
Number of subjects: 310
Study 23666976 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate (75%) and low protein (3%) diet
Number of subjects: 20
Study 23666976 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate and normal protein (20%) diet
Number of subjects: 20
Study 23666976 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat (46%) and low protein diet
Number of subjects: 20
Study 23666976 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat (60%) and normal protein diet
Number of subjects: 20
Study 23666976 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced diet (50% carbohydrates, 20% protein)
Number of subjects: 20
Study 23666976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping EE during overfeeding diets containing 20% protein
Number of subjects: 20
Study 23666976 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein overfeeding
Number of subjects: 20
Study 21864718 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate, group-based behavioral and social support intervention including 16 weekly group sessions and 8 weeks of telephone maintenance counseling.
Number of subjects: 155
Study 21864718 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control group receiving 16 weekly health education mailings.
Number of subjects: 155
Study 20386476 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation (EMS) training program applied on quadriceps muscles over 5 weeks
Number of subjects: 20
Study 20386476 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMS training)
Number of subjects: 20
Study 17555707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group program for spouses of stroke patients (15 bi-monthly 1.5 hour sessions)
Number of subjects: 38
Study 17555707 — intervention group
Group type: COMPARATOR
Intervention: Informational support (control group)
Number of subjects: 38
Study 17555707 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 38
Study 15776275 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 200 mg/day for 6 days
Number of subjects: 11
Study 15776275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11919661 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg daily
Number of subjects: 14
Study 11919661 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine 4 mg/placebo on alternating days
Number of subjects: 14
Study 11919661 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 16 mg daily
Number of subjects: 14
Study 11919661 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine 32 mg/placebo on alternating days
Number of subjects: 14
Study 11919661 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose buprenorphine (regardless of schedule)
Number of subjects: 14
Study 10227757 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 15
Study 10227757 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 15
Study 9764864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 104
Study 9764864 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 104
Study 2526341 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 7
Study 2526341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 835509 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified grain products daily for 6 to 8 months
Number of subjects: 221
Study 835509 — intervention group
Group type: COMPARATOR
Intervention: Same foods without added iron (Control)
Number of subjects: 221
Study 835509 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ferrous sulfate administration for those with hemoglobin levels below 13 g/dl
Number of subjects: 221
Study 31280965 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-cm excision margin
Number of subjects: 936
Study 31280965 — intervention group
Group type: COMPARATOR
Intervention: 4-cm excision margin
Number of subjects: 936
Study 27622611 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.2 mg
Number of subjects: 86
Study 27622611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 24643757 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Communication intervention (Comunicación Familiar), delivered in six sessions lasting 2 hours each after school.
Number of subjects: 0
Study 23317054 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal (LM)
Number of subjects: 19
Study 22195390 — intervention group
Group type: EXPERIMENTAL
Intervention: 48‐h sleep‐deprived
Number of subjects: 35
Study 22195390 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 19103729 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd-p53 combined with RT
Number of subjects: 82
Study 19103729 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 82
Study 17016589 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 null genotype
Number of subjects: 367
Study 17016589 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 367
Study 17016589 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 null genotype and smoking interaction
Number of subjects: 367
Study 12720233 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mm Crossflex stent (n = 112)
Number of subjects: 223
Study 12720233 — intervention group
Group type: COMPARATOR
Intervention: 16 mm NIR stent (n = 111)
Number of subjects: 223
Study 11035447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural activity for a two-month period
Number of subjects: 19
Study 11035447 — intervention group
Group type: COMPARATOR
Intervention: No cultural activity (control group)
Number of subjects: 19
Study 11035447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural activity
Number of subjects: 19
Study 11035447 — intervention group
Group type: COMPARATOR
Intervention: Non-culturally stimulated group (control)
Number of subjects: 19
Study 11035447 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 19
Study 9377917 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line heat moisture exchanging filter (HMEF)
Number of subjects: 280
Study 9377917 — intervention group
Group type: COMPARATOR
Intervention: Heated wire humidifier (H-wH)
Number of subjects: 280
Study 8408137 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy and division of all plicae
Number of subjects: 30
Study 8408137 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic arthroscopy alone
Number of subjects: 30
Study 8408137 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent division of plicae after another arthroscopic operation
Number of subjects: 30
Study 2430506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine combined with oral penicillin-V (twice daily)
Number of subjects: 40
Study 2430506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine combined with benzathine penicillin (intramuscularly every 4 weeks)
Number of subjects: 40
Study 2430506 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 40
Study 30237467 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laser PRP
Number of subjects: 39
Study 30237467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern scan laser (PASCAL) PRP
Number of subjects: 39
Study 30237467 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 39
Study 26584450 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 1098
Study 26584450 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 1098
Study 26584450 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser plus 0.5 mg ranibizumab
Number of subjects: 1098
Study 26584450 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab + laser
Number of subjects: 1098
Study 26584450 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 1098
Study 26584450 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 1098
Study 24745701 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen sublingual immunotherapy
Number of subjects: 56
Study 24745701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 23444750 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation with antioxidant agents containing alpha lipoic acid (ALA) plus calcium and vitamin D3 (n = 25)
Number of subjects: 50
Study 23444750 — intervention group
Group type: COMPARATOR
Intervention: Only calcium and vitamin D3 (n = 25)
Number of subjects: 50
Study 20375919 — intervention group
Group type: EXPERIMENTAL
Intervention: Drains (group I, 20 patients)
Number of subjects: 39
Study 20375919 — intervention group
Group type: COMPARATOR
Intervention: No drains (group II, 19 patients)
Number of subjects: 39
Study 20375919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group I and group II)
Number of subjects: 39
Study 17943615 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based intervention programme
Number of subjects: 54
Study 17943615 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 54